VIRACTA THERAPEUTICS
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
VIRACTA THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Medical Oncology Pharmaceutical Therapeutics
Founded:
2007-01-01
Address:
Cardiff By The Sea, California, United States
Country:
United States
Website Url:
http://www.viracta.com
Total Employee:
11+
Status:
Active
Contact:
(858)400-8470
Email Addresses:
[email protected]
Total Funding:
234.9 M USD
Technology used in webpage:
HSTS Linode Ninja Forms SMTP2GO
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Delcath Systems
Delcath Systems and its proprietary targeted drug delivery system are at the forefront of the regional treatment of cancer.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
MEI Pharma
MEI Pharma is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Olema Oncology
Olema Oncology is a preclinical biotechnology company that develops new drugs for the treatment and prevention of breast cancer.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-11-30 | Sunesis Pharmaceuticals | Sunesis Pharmaceuticals acquired by Viracta Therapeutics | N/A |
Investors List
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Viracta Therapeutics
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Viracta Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Post-IPO Equity - Viracta Therapeutics
Logos Capital
Logos Capital investment in Post-IPO Equity - Viracta Therapeutics
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - Viracta Therapeutics
LifeSci Venture Partners
LifeSci Venture Partners investment in Post-IPO Equity - Viracta Therapeutics
aMoon Fund
aMoon Fund investment in Post-IPO Equity - Viracta Therapeutics
Sectoral Asset Management
Sectoral Asset Management investment in Post-IPO Equity - Viracta Therapeutics
Ridgeback Capital
Ridgeback Capital investment in Post-IPO Equity - Viracta Therapeutics
Biotechnology Value Fund
Biotechnology Value Fund investment in Post-IPO Equity - Viracta Therapeutics
Key Employee Changes
Official Site Inspections
http://www.viracta.com Semrush global rank: 5.56 M Semrush visits lastest month: 1.3 K
- Host name: 104.21.54.133
- IP address: 104.21.54.133
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Viracta Therapeutics"
Viracta Therapeutics - Crunchbase Company Profile & Funding
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with …See details»
Company | Viracta Therapeutics, Inc.
Advancing new medicines to benefit patients with virus associated cancers and other serious diseasesSee details»
Leadership - Viracta Therapeutics, Inc.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you …See details»
Viracta Pharmaceuticals - Org Chart, Teams, Culture & Jobs - The …
View Viracta Pharmaceuticals' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Viracta | Investor Relations - Board of Directors
Prior to joining Viracta, Mr. Rothera served as President and CEO of Silence Therapeutics (NASDAQ: SLN), a clinical-stage organization focused on developing RNA therapies for …See details»
Viracta | Investor Relations - Welcome
Nov 6, 2024 Viracta is a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta’s lead product candidate is …See details»
Viracta Therapeutics - Contacts, Employees, Board Members, …
Organization. Viracta Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. ... Viracta Therapeutics has 7 …See details»
Viracta Therapeutics - Funding, Financials, Valuation & Investors
Viracta Therapeutics is registered under the ticker NASDAQ:VIRX . Viracta Therapeutics is funded by 21 investors. Oxford Finance LLC and Silicon Valley Bank are the most recent …See details»
Viracta Therapeutics Announces Reprioritization of Resources to …
Nov 6, 2024 Roger J. Pomerantz, M.D., Chairman of Viracta’s Board, stated, “Viracta has adjusted its organization to further focus on the advancement of Nana-val in EBV-positive …See details»
Viracta Therapeutics Inc Company Profile - Overview
Viracta Therapeutics Inc (Viracta) is a biopharmaceutical company. It is primarily engaged in the development of therapeutics for the treatment of virus-associated cancers. The company's …See details»
Viracta | Investor Relations - News Releases
Nov 13, 2024 Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update ... we recently announced a reprioritization of resources intended to right …See details»
Mark Rothera | Viracta Therapeutics, Inc.
Mark Rothera joined Viracta as President, Chief Executive Officer and Director in September 2022. Mr. Rothera brings more than 30 years of experience in the biopharmaceutical industry, …See details»
Viracta Therapeutics - Overview, News & Similar companies
May 17, 2024 Viracta Therapeutics Announces New Employment Inducement Grants SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a …See details»
Viracta Therapeutics - Craft
Sep 12, 2024 Viracta’s proprietary platform is a highly targeted combination therapy approach for virus-associated malignancies. The Company's initial focus is on cancers associated with …See details»
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical
4 days ago Viracta assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation. Contact Information:See details»
Viracta | Investor Relations - News Releases
Nov 6, 2024 Roger J. Pomerantz, M.D., Chairman of Viracta’s Board, stated, “Viracta has adjusted its organization to further focus on the advancement of Nana-val in EBV-positive …See details»
Viracta Therapeutics announces exploration of strategic …
4 days ago Viracta Therapeutics (VIRX) announced that its Board of Directors has initiated a process to explore a broad range of strategic alternatives. To maximize its cash runway while …See details»
Viracta Therapeutics, Inc. (VIRX) - Yahoo Finance
Find the latest Viracta Therapeutics, Inc. (VIRX) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Viracta | Investor Relations - News Releases
Aug 14, 2024 Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive …See details»
Viracta Therapeutics Engages In Strategic Alternatives, Closes
4 days ago Viracta said it has elected to close its ongoing pivotal Phase 2 clinical trial of Nana-val in relapsed/refractory EBV+ lymphomas (the NAVAL-1 trial). The company emphasized …See details»